MacfarlaneJ. The clinical impact of pneumococcal disease. In
Mayon-WhiteR. T.
(ed) The clinical impact of pneumococcal disease and strategies for its prevention (International Congress and Symposium Series 210) London: Royal Society of Medicine; 19959–17
MacfarlaneJ. T.,
ColvilleA.,
GuionA.,
MacfarlaneR. M.,
RoseD. H. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet1993; 341:511–514
RobbinsJ. B.,
AustrianR.,
LeeC.-J. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis1983; 148:1136–1159
FineM. J.,
SmithM. A.,
CarsonC. A. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med1994; 154:2666–2677
SimberkoffM. S.,
CrossA. P.,
Al-IbrahimM. Efficacy of pneumococcal vaccine in high risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med1986; 315:1318–1327
SimsR. V.,
SteinmannW. C.,
McConvilleJ. H.,
KingL. R.,
ZwickW. C.,
SchwartzJ. S. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med1988; 108:653–657
BolanG.,
BroomeC. V.,
FacklamR. R.,
PlikaytisB. D.,
FraserD. W.,
SchlechW. F. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med1986; 104:1–6
MäkeläP. H. Cost benefit analysis of pneumococcal vaccination. In
Mayon-WhiteR. T.
(ed) The clinical impact of pneumococcal disease and strategies for its prevention (International Congress and Symposium Series 210) London: Royal Society of Medicine; 199541–47